Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

References

• DrakeLACeilleyRICornelisonRLGuidelines of care for psoriasisJ Am Acad Dermatol199428632637
   Web of Science ®Google Scholar
• DanielsenKOlsenAOWilsgaardTFurbergASIs the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohortBr J Dermatol20131681303131023374051
   PubMed Web of Science ®Google Scholar
• Taltz [package insert]Eli Lilly and CompanyIndianapolis, IN2016
   Google Scholar
• Di cesareADi meglioPNestleFOThe IL-23/Th17 axis in the immunopathogenesis of psoriasisJ Invest Dermatol200912961339135019322214
   PubMed Web of Science ®Google Scholar
• IwakuraYIshigameHThe IL-23/IL-17 axis in inflammationJ Clin Invest200611651218122216670765
   PubMed Web of Science ®Google Scholar
• LowesMASuárez-fariñasMKruegerJGImmunology of psoriasisAnnu Rev Immunol20143222725524655295
   PubMed Web of Science ®Google Scholar
• LowesMAKikuchiTFuentes-duculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol200812851207121118200064
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPRole of IL-17 in psoriasis and psoriatic arthritisClin Rev Allergy Immunol201344218319322362575
   PubMed Web of Science ®Google Scholar
• ArizaMEWilliamsMVWongHKTargeting IL-17 in psoriasis: from cutaneous immunobiology to clinical applicationClin Immunol2013146213113923314273
   PubMed Web of Science ®Google Scholar
• MartinDATowneJEKricorianGThe emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsJ Invest Dermatol20131331172622673731
   PubMed Web of Science ®Google Scholar
• WeaverCTHattonRDManganPRHarringtonLEIL-17 family cytokines and the expanding diversity of effector T cell lineagesAnnu Rev Immunol20072582185217201677
   PubMed Web of Science ®Google Scholar
• GaffenSLStructure and signalling in the IL-17 receptor familyNat Rev Immunol20099855656719575028
   PubMed Web of Science ®Google Scholar
• GiuntaAVenturaAChimentiMSBianchiLEspositoMSpotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapyDrug Des Devel Ther20171116431651
   PubMed Web of Science ®Google Scholar
• KruegerJGFretzinSSuárez-fariñasMIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJ Allergy Clin Immunol20121301145.e9154.e922677045
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535627299809
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
   PubMed Web of Science ®Google Scholar
• SyedYYIxekizumab: a review in moderate to severe plaque psoriasisAm J Clin Dermatol201718114715828138946
   PubMed Web of Science ®Google Scholar
• BlauveltAPappKASofenHContinuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisJ Eur Acad Dermatol Venereol20173161004101328190255
   PubMed Web of Science ®Google Scholar
• ReichKPuigLMallbrisLZhangLOsuntokunOLeonardiCThe effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasisJ Eur Acad Dermatol Venereol20173171196120728370467
   PubMed Web of Science ®Google Scholar
• GottliebABLacourJPKormanNTreatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studiesJ Eur Acad Dermatol Venereol201731467968527696577
   PubMed Web of Science ®Google Scholar
• ReichKPinterALacourJPComparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyBr J Dermatol Epub2017519
   Web of Science ®Google Scholar
• MenterAWarrenRBLangleyRGEfficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, -2, and -3)J Eur Acad Dermatol Venereol Epub2017321
   Web of Science ®Google Scholar
• Van de kerkhofPGuentherLGottliebABIxekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3J Eur Acad Dermatol Venereol201731347748227910156
   PubMed Web of Science ®Google Scholar
• SaekiHNakagawaHIshiiTEfficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasisJ Eur Acad Dermatol Venereol20152961148115525355284
   PubMed Web of Science ®Google Scholar
• SaekiHNakagawaHNakajoKEfficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)J Dermatol201744435536227726163
   PubMed Web of Science ®Google Scholar
• LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med2012366131190119922455413
   PubMed Web of Science ®Google Scholar
• GordonKBLeonardiCLLebwohlMA 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJ Am Acad Dermatol20147161176118225242558
   PubMed Web of Science ®Google Scholar
• LangleyRGRichPMenterAImprovement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol20152991763177025693783
   PubMed Web of Science ®Google Scholar
• LeonardiCLBlauveltASofenHLRapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3J Eur Acad Dermatol Venereol20173191483149028294430
   PubMed Web of Science ®Google Scholar
• GuentherLWarrenRBCatherJCImpact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12 week results from two Phase 3 trialsJ Eur Acad Dermatol Venereol Epub201762
   Web of Science ®Google Scholar
• ReichAHrehorówESzepietowskiJCPruritus is an important factor negatively influencing the well-being of psoriatic patientsActa Derm Venereol201090325726320526542
   PubMed Web of Science ®Google Scholar
• HsuLSnodgrassBTArmstrongAWAntidrug antibodies in psoriasis: a systematic reviewBr J Dermatol2014170226127324117166
   PubMed Web of Science ®Google Scholar
• MuramTSJChainJKomocsarWP87: a highly sensitive and drug-tolerant immunogenicity screening assay for ixekizumab, an anti-interleukin-17A antibody, using an affinity capture elution approach7th International Congress of Psoriasis: from Gene to Clinic18122014The Queen Elizabeth II Conference CentreLondon, UK11th-13th December 2014
   Google Scholar
  Br J Dermatol2014e105e173
   Web of Science ®Google Scholar
• BlauveltACameronGGordonKIxekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis [abstract no. 3232]J Am Acad Dermatol2016745 Suppl 1AB258
   Google Scholar
• FarahnikBBeroukhimKZhuTHIxekizumab for the treatment of psoriasis: a review of phase III trialsDermatol Ther (Heidelb)201661253726910853
   PubMed Web of Science ®Google Scholar
• StroberBLeonardiCPappKAShort- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated dataJ Am Acad Dermatol2017763432.e17440.e1727889292
   PubMed Web of Science ®Google Scholar